Ewa Galaj1, Monica Manuszak2, Sandra Babic2, Subramaniam Ananthan3, Robert Ranaldi4. 1. CUNY Graduate Center, New York, NY, United States. 2. Queens College of the City University of New York, Department of Psychology, Flushing, NY, United States. 3. Department of Chemistry, Drug Discovery Division, Southern Research Institute, Birmingham, AL, United States. 4. CUNY Graduate Center, New York, NY, United States; Queens College of the City University of New York, Department of Psychology, Flushing, NY, United States. Electronic address: Robert.Ranaldi@qc.cuny.edu.
Abstract
BACKGROUND: Because the role of dopamine (DA) D3 receptors has been investigated primarily in relation to cocaine-related behaviors little is known of the role of these receptors in heroin seeking. PURPOSES: To investigate the effect of the selective DA D3 receptor antagonist, SR 21502, on cue-induced reinstatement of heroin seeking and heroin conditioned place preference (CPP). METHODS: In experiment 1, rats were trained to self-administer intravenous heroin for 15 days followed by extinction. Following extinction animals were treated with one of several SR 21502 doses (0, 7.5, 10 or 15mg/kg) and a cue-induced reinstatement test was conducted. In experiment 2, animals were conditioned to experience heroin in one compartment of a CPP apparatus and saline in the other. On the test day animals were treated with 0, 3.75, 7.5, 10 or 15mg/kg of SR 21502 and tested for their CPP. RESULTS: The results from experiment 1 showed a significant dose-related reduction in cue-induced reinstatement of active lever pressing in the 7.5 and 10mg groups and an absence of the reinstatement effect in the 15mg group. In experiment 2, animals treated with vehicle or 3.75mg of SR 21502 showed significant heroin place preferences but those treated with the higher doses showed no CPP. CONCLUSIONS: Our findings suggest that DA D3 receptors play a significant role in heroin approach behaviors driven by conditioned stimuli. As such, we propose that SR 21502 holds potential as an effective pharmacotherapeutic agent for relapse prevention and should be studied further.
BACKGROUND: Because the role of dopamine (DA) D3 receptors has been investigated primarily in relation to cocaine-related behaviors little is known of the role of these receptors in heroin seeking. PURPOSES: To investigate the effect of the selective DA D3 receptor antagonist, SR 21502, on cue-induced reinstatement of heroin seeking and heroin conditioned place preference (CPP). METHODS: In experiment 1, rats were trained to self-administer intravenous heroin for 15 days followed by extinction. Following extinction animals were treated with one of several SR 21502 doses (0, 7.5, 10 or 15mg/kg) and a cue-induced reinstatement test was conducted. In experiment 2, animals were conditioned to experience heroin in one compartment of a CPP apparatus and saline in the other. On the test day animals were treated with 0, 3.75, 7.5, 10 or 15mg/kg of SR 21502 and tested for their CPP. RESULTS: The results from experiment 1 showed a significant dose-related reduction in cue-induced reinstatement of active lever pressing in the 7.5 and 10mg groups and an absence of the reinstatement effect in the 15mg group. In experiment 2, animals treated with vehicle or 3.75mg of SR 21502 showed significant heroin place preferences but those treated with the higher doses showed no CPP. CONCLUSIONS: Our findings suggest that DA D3 receptors play a significant role in heroin approach behaviors driven by conditioned stimuli. As such, we propose that SR 21502 holds potential as an effective pharmacotherapeutic agent for relapse prevention and should be studied further.
Authors: Chloe J Jordan; Bree A Humburg; Eric B Thorndike; Anver Basha Shaik; Zheng-Xiong Xi; Michael H Baumann; Amy Hauck Newman; Charles W Schindler Journal: J Pharmacol Exp Ther Date: 2019-09-27 Impact factor: 4.030
Authors: Hazem E Hassan; Deanna Kelly; Moshe Honick; Sagar Shukla; Ahmed Ibrahim; David A Gorelick; Matthew Glassman; Robert P McMahon; Heidi J Wehring; Ann Marie Kearns; Stephanie Feldman; Mingming Yu; Ken Bauer; Jia Bei Wang Journal: J Clin Pharmacol Date: 2016-08-04 Impact factor: 3.126
Authors: David J Reiner; Ida Fredriksson; Olivia M Lofaro; Jennifer M Bossert; Yavin Shaham Journal: Neuropsychopharmacology Date: 2018-10-06 Impact factor: 7.853
Authors: Ida Fredriksson; Sarah V Applebey; Angelica Minier-Toribio; Aniruddha Shekara; Jennifer M Bossert; Yavin Shaham Journal: Neuropsychopharmacology Date: 2020-01-06 Impact factor: 7.853
Authors: Scott T Ewing; Chris Dorcely; Rivka Maidi; Gulsah Paker; Eva Schelbaum; Robert Ranaldi Journal: Addict Biol Date: 2021-01-25 Impact factor: 4.093
Authors: Christian A Botz-Zapp; Stephanie L Foster; Desta M Pulley; Briana Hempel; Guo-Hua Bi; Zheng-Xiong Xi; Amy Hauck Newman; David Weinshenker; Daniel F Manvich Journal: Behav Brain Res Date: 2021-08-02 Impact factor: 3.352